Zhifei Biological announced the approval of its adsorbed acellular DTaP-Hib vaccine. This vaccine combines protection against diphtheria, tetanus, pertussis, and Haemophilus influenzae type b. The approval signifies an expansion of Zhifei's pediatric vaccine portfolio, aiming to provide comprehensive immunization against common childhood diseases.
The approval of this combination vaccine by Zhifei Biological enhances its pediatric vaccine portfolio, offering a more convenient and comprehensive immunization option for children against four major diseases. This move strengthens its market position in the highly competitive childhood vaccine segment and addresses public health needs for integrated disease prevention.
Zhifei Biological's DTaP-Hib vaccine has been approved.
The vaccine offers combined protection against diphtheria, tetanus, pertussis, and Hib.
This expands the company's pediatric vaccine offerings.
The approval of this combination vaccine by Zhifei Biological enhances its pediatric vaccine portfolio, offering a more convenient and comprehensive immunization option for children against four major diseases. This move strengthens its market position in the highly competitive childhood vaccine segment and addresses public health needs for integrated disease prevention.
The vaccine offers combined protection against diphtheria, tetanus, pertussis, and Hib.
This expands the company's pediatric vaccine offerings.
Sign in to save notes on signals.
Sign In